Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Compass Therapeutics's Enterprise Value is $148.18 Mil.
Compass Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $-56.63 Mil. Therefore, Compass Therapeutics's EV-to-EBIT ratio for today is -2.62.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Compass Therapeutics's Enterprise Value is $148.18 Mil.
Compass Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was $-54.88 Mil. Therefore, Compass Therapeutics's EV-to-EBITDA ratio for today is -2.70.
Compass Therapeutics Enterprise Value Historical Data
The historical data trend for Compass Therapeutics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Compass Therapeutics's Enterprise Value
For the Biotechnology subindustry, Compass Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compass Therapeutics's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Compass Therapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Compass Therapeutics's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Compass Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compass Therapeutics (NAS:CMPX) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Compass Therapeutics's current Enterprise Value is $148.18 Mil.
Compass Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-56.63 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Compass Therapeutics's current Enterprise Value is $148.18 Mil.
Compass Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-54.88 Mil.
Compass Therapeutics's current Enterprise Value is $148.18 Mil.
Compass Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.85 Mil.
Compass Therapeutics's current Enterprise Value is $148.18 Mil.
Compass Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-44.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compass Therapeutics Enterprise Value Related Terms
Thank you for viewing the detailed overview of Compass Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CMPX has been successfully added to your 